CAMBRIDGE, Mass.–(BUSINESS WIRE)–Compass
Therapeutics, a clinical-stage biotechnology company targeting the
human immune synapse with a new generation of monoclonal and
multispecific antibody therapeutics, today announced that the U.S.
Patent and Trademark Office issued three U.S. patents covering certain
anti-CD137 antibodies, including its lead therapeutic candidate, CTX-471.
CTX-471 is a fully human antibody that binds and activates a unique
epitope of the co-stimulatory receptor CD137 (4-1BB) expressed on T- and
NK-cells. In preclinical studies, CTX-471 demonstrates potent
monotherapy activity in multiple syngeneic tumor models, including
curative efficacy against very large, established tumors where other
validated IO antibodies, such as antibodies targeting PD-1, PD-L1,
CTLA-4 and OX40 have no or minimal effect. CTX-471 efficacy is
associated with a comprehensive reprogramming of the tumor
microenvironment, increasing CD8+ T-cell infiltration and penetration
while reducing T-cell exhaustion. Unlike other clinical and preclinical
CD137 antibodies, CTX-471 shows no evidence of hepatic toxicity in both
mice and non-human primates, supporting the potential for a wide
therapeutic window in patients.
The CTX-471 Phase 1 study is now open. For more information: https://clinicaltrials.gov/ct2/show/NCT03881488
“We’re truly excited about the promise CTX-471 holds for patients with
cancer and we’re delighted to secure these patents, which affirm the
novelty of our approach,” said Thomas Schuetz, MD, PhD, the scientific
founder and chief executive officer of Compass. “The intellectual
property portfolio we have generated at Compass provides an excellent
foundation for us to build on as we continue to advance our pipeline of
innovative therapeutic candidates in oncology and autoimmunity.”
The newly issued patents are: U.S. Patent No. 10,279,038, which covers
the composition of CTX-471; and U.S. Patent Nos. 10,279,039 and
10,279,040, which cover the use of CTX-471 in methods for treating
cancer and inducing or enhancing an anti-tumor immune response,
respectively. The base term for each patent extends until July of 2038.
Additional patent filings by Compass related to CTX-471 are under review.
About Compass Therapeutics
Compass Therapeutics is a
clinical-stage biotechnology company targeting the immune synapse with a
new generation of monoclonal and multispecific antibody therapeutics.
Compass has broadly drugged the immune system by generating epitopically
diverse antibody panels to more than 40 targets across all immune cell
types and is leveraging its proprietary StitchMabsTM and
common light-chain based multispecific platforms to empirically identify
combinations and multispecifics with optimized activity. The company’s
lead product candidate, CTX-471, is a fully human agonistic antibody of
CD137, which is in a Phase 1 study in patients with inadequate responses
to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several
pre-clinical assets including a novel class of NK-cell engaging
bispecifics targeting NKp30 and multiple bispecific checkpoint programs.
The company’s offices and labs are based in Kendall Square in Cambridge,
Mass.
Contacts
Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333